Skip to main content

Thermo Fisher Scientific Inc (TMO) Stock Analysis

SellModerate Confidence

Healthcare · Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences... Read more

$488.96+15.3% upside
Score 5.1/10Target $564.36Reward/Risk 1.7:1

TrendMatrix rates Thermo Fisher Scientific Inc (TMO) as Sell with moderate confidence. The stock trades at $488.96 with +15.3% upside to the $564.36 price target. Overall score: 5.1/10 across 10 analysis dimensions. Reward/risk ratio: 1.7:1.

Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: moderate.

Val5.5Qual5.9Grw4.1Mom4.9Sent6.1Ins3.2Peer4.1Tech5.1Risk7.55.1OVERALL

Investment Thesis

+ Earnings catalyst in 28 days
+ Strong earnings beat streak (4/4)
- Negative news sentiment (-0.67)
- Below 200-day MA

Fundamentals

P/E (TTM)27.6
P/E (Fwd)18.2
Mkt Cap$181.9B
EV/EBITDA18.8
Profit Mgn15.0%
ROE13.0%
Rev Growth7.2%
Beta0.97
Dividend0.37%
Analysts33
Frequently Asked Questions
Is TMO stock a buy right now?

TrendMatrix rates Thermo Fisher Scientific Inc (TMO) as Sell with moderate confidence. Score 5.1/10.

What is the TMO stock price target?

Take-profit target: $564.36 (+15.3% upside). Reward/risk ratio: 1.7:1. Stop-loss: $444.59.

What are the risks of investing in TMO?

Negative news sentiment (-0.67); Below 200-day MA.

Is TMO overvalued or undervalued?

Thermo Fisher Scientific Inc trades at a P/E of 27.6 (forward 18.2). TrendMatrix value score: 5.5/10. Verdict: Sell.

What do analysts say about TMO?

33 analysts cover TMO with a consensus score of 4.2/5. Average price target: $664.

What does Thermo Fisher Scientific Inc do?Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and...

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Related stocks: MTD (Mettler-Toledo International, I) · IQV (IQVIA Holdings, Inc.) · ILMN (Illumina, Inc.) · EXAS (Exact Sciences Corporation) · WAT (Waters Corporation)
37 NEUTRAL
<20d<50d<200dGOLDEN CROSSSupp $458.34Res $520.75

Price Targets

$445
$564
Upside+15.3%
Reward/Risk1.7:1

Position Sizing

ConvictionNONE
Suggested %0.5%
Max %1%
RegimeCAUTIOUS

Risk Alerts

! MOMENTUM:4.9<5.0
CATALYSTSuitability: Moderate
Risk/Reward 2.4>=2.0
Insider activity: OK
No SEC red flags
Momentum 4.9<5.0